Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Quarterly Earnings Results, Beats Expectations By $0.53 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its earnings results on Thursday. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.53, Zacks reports. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%.

Zealand Pharma A/S Stock Down 2.7%

ZLDPF stock traded down $1.68 during midday trading on Thursday, reaching $60.42. The company had a trading volume of 2,161 shares, compared to its average volume of 2,688. The company has a 50 day moving average of $69.05 and a two-hundred day moving average of $70.46. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02. Zealand Pharma A/S has a 1 year low of $49.98 and a 1 year high of $101.29. The company has a market capitalization of $4.29 billion, a P/E ratio of 4.35 and a beta of 0.72.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ZLDPF shares. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Five investment analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.